Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer

Oral Oncology

Volumn 47, Issue 8, 2011, Pages 763-767

  Halamka, Magdalena ^a   Cvek, Jakub ^a   Kubes, Jiri ^b   Zavadova, Eva ^c   Kominek, Pavel ^a   Horacek, Jaroslav ^a   Dusek, Ladislav ^d   Feltl, David ^a  

^a UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^b UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Celecoxib; COX 2 expression; Head and neck cancer; Radiotherapy; VEGF

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD LEVEL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DERMATITIS; DRUG DOSE ESCALATION; DYSPHAGIA; FATIGUE; FEMALE; GENE EXPRESSION; HEAD AND NECK CANCER; HEARTBURN; HUMAN; KIDNEY DYSFUNCTION; LARYNX EDEMA; LEUKOPENIA; LIVER DISEASE; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION SICKNESS; SIDE EFFECT; THRUSH; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960700239     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.05.009     Document Type: Article

References (53)

1. J.H. Won Cyclooxygenase-2: a potential target in human cancer Canc Treat Res 36 3 2004 161 162
2. D.G. Haller COX-2 inhibitors in oncology Semin Oncol 30 4 Suppl. 12 2003 2 8 (Pubitemid 37122557)
3. B.W. Chang, D.H. Kim, and D.P. Kowalski Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma Clin Cancer Res 10 2004 1678 1684 (Pubitemid 38435558)
4. P. Nix, M. Lind, and J. Greenman Expression of cox-2 protein in radioresistant laryngeal cancer Ann Oncol 15 2004 797 801 (Pubitemid 38714743)
5. N. Teracado, S. Shintani, and J. Yano Overexpression of cyclooxygenase-2 is associated with radioresistence in oral squamous cell carcinoma Oral Oncol 40 2004 383 389 (Pubitemid 38221385)
6. P. Sminia, G. Kuipers, and A. Geldof COX-2 inhibitors act as radiosensitiser in tumour treatment Biomed Pharmacother 59 2005 272 275
7. A.T. Koki, K.M. Leathy, and J.L. Masferrer Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy Expert Opin Invest Drugs 8 1999 1623 1638 (Pubitemid 29460527)
8. O. Gallo, A. Franchi, and L. Magnelli Cycloocygenase-2 pathway correlates with vegf expression in head and neck cancer. Implication for tumor angiogenesis and metastasis Neoplasia 3 1 2001 53 61 (Pubitemid 32201610)
9. M. Tsujii, S. Kawano, and S. Tsuji Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 93 1998 705 716 (Pubitemid 28257578)
10. L. Milas Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse Semin Radiat Oncol 11 2001 290 299 (Pubitemid 32959664)
11. Z. Liao, K.A. Mason, and L. Milas Cyclo-oxygenase-2 and its inhibition in cancer. Is there a role? Drugs 67 6 2007 821 845 (Pubitemid 46607385)
12. C.H. Snyderman Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer Head Neck 24 2002 792 799
13. D.T. Lin, K. Subbaramiah, and J.P. Shah Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer (review) Head Neck 24 2002 792 799 (Pubitemid 34857307)
14. J. Subd, and A. Reith Which putatively pre-malignant oral lesions become oral cancer? J Oral Pathol Med 32 2003 63 70
15. S. Gately The contributions of cylooxygenase-2 to tumor angiogenesis Cancer Metast Rev 19 2000 19 27
16. B. Zweifel, R. Omberg, and M. Woerner Inhibition of prostaglandins by celecoxib results in suppression of tumor growth, reduces VEGF levels in human head, neck xenograft model Proc Am Assoc Cancer Res 43 2001 77
17. M.L. Leathy, R.L. Ornberg, and Y. Wang Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vitro Cancer Res 62 2002 625 631 (Pubitemid 34126930)
18. J. Masferrer Approach to angiogenesis inhibition based on cyclooxygenase-2 Cancer J 7 Suppl. 2001 144 150
19. H. Sawaoka, S. Tsuji, and M. Tsujii Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo Lab Invest 79 1999 1469 1477 (Pubitemid 30013912)
20. X.H. Liu, A. Kirschenbaum, and S. Yao Inhibition of cyclooxgenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo J Urol 164 2000 820 825 (Pubitemid 30637640)
21. J.L. Mansferrer, K.M. Leathy, and A.T. Koki Antiangiogenic and antitumor activities of cyclooxygenase-2 Inhibitors Cancer Res 60 2000 1306 1311 (Pubitemid 30151999)
22. D. Wei, L. Wang, and Y. He Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity Cancer Res 64 6 2004 2030 2038 (Pubitemid 38339450)
23. L. Milas, K. Kishi, and N. Hunter Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme J Natl Cancer I 91 17 1999 1501 1504 (Pubitemid 29424556)
24. K. Kishi, S. Petersen, and C. Petersen Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor Cancer Res 60 2000 1326 1331 (Pubitemid 30152002)
25. O. Dormond, and C. Rüegg Inhibition of tumor angiogenesis by non-steroidal anti-inflamatory drugs: emerging mechanisms and therapeutic perspectives Drug Resist Update 4 2002 314 321 (Pubitemid 34456385)
26. K.H. Dittmann, K. Mayer, and P.A. Ohneseit Celecoxib induces tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism Int J Radiat Oncol 70 1 2008 203 212 (Pubitemid 350251053)
27. C.Y. Yang, C.L. Meng, and C.L. Liao Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines Prostag Oth Lipid M 72 2003 115 130 (Pubitemid 37346179)
28. Z. Wang, C.F. Fuentes, and S.M. Shapshay Angiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell Laryngoscope 122 2002 839 843 (Pubitemid 34477613)
29. H. Pyo, H. Choy, and G.P. Amorino A selective cyclooxygenase -2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2 Clin Cancer Res 7 2001 2998 3005 (Pubitemid 32963816)
30. C. Petersen, S. Petersen, and L. Milas Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor Clin Cancer Res 6 2000 2513 2520 (Pubitemid 30399223)
31. Y. Futura, N. Hunter, and Y. Barkley Jr Increase in radioresponse of murine tumors by treatment with indomethacin Cancer Res 48 1988 3008 3013
32. L. Milas, Y. Futura, and N. Hunter Dependance of indomenthacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence Cancer Res 50 1990 4473 4477 (Pubitemid 20230378)
33. C. Petersen, S. Petersen, and L. Milas Human glioma cell radiosensitisation bu a selective COX-2 inhibitor Clin Cancer Res 6 2000 2513 2520
34. B. Weppelmann, and D. Monkemeier The influence of prostaglandin antagonists on radiation therapy of carcinoma of cervix Gynecol Oncol 17 1984 196 199 (Pubitemid 14193205)
35. T.W. Davis, J.M. O'Neal, and M.D. Pagle Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature Cancer Res 64 2004 279 285 (Pubitemid 38114108)
36. Y.K. Shin, J.S. Park, and H.S. Kim Radiosensitivity enhancement by celecoxib, a cyclooxygenase(COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels Cancer Res 65 20 2005 9501 9509 (Pubitemid 41508020)
37. T.A. Rich, and R. Shepard COX-2 inhibitors as radiation sensitisers for upper GI tract cancer: esopahgus, stomach, and pancreas Am J Clin Oncol 26 4 Suppl. 2 2003 S110 S113
38. D.H. Gorski, M.A. Beckett, and N.T. Jaskowiak Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378 (Pubitemid 29334495)
39. N. Terakado, S. Shintani, and J. Yano Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma Oral Oncol 40 2004 383 389 (Pubitemid 38221385)
40. T. Joki, O. Heese, and D.C. Niklas Expression of cyclooxygenase-2 in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398 Cancer Res 60 2000 4926 4931
41. U. Raju, H. Ariga, and K. Dittmann Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, Celecoxib Int J Radiat Onco 63 2 2005 520 528 (Pubitemid 41317170)
42. Z. Laio, L. Milas, and R. Komaki Combination of COX-2 inhibitor with radiotherapy or radiochemotherapy in treatment of thoracic cancer Am J Clin Oncol (CCT) 26 4 Suppl. 2 2003 85 91
43. U. Ganswindt, V. Budach, and V. Jendrossek Combination of celecoxib with percutaneus radiotherapy in patients with localised prostate cancer-a phase I study Radiat Oncol 2006 1 9
44. M.M. Javle, S. Cao, and F.A. Durrani Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecanand 5-fluorouracil Clin Cancer Res 13 3 2007 965 971 (Pubitemid 46340374)
45. S.J. Dawson, M. Michael, and J. Biagi A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer [Abstract] Invest New Drugs 25 2 2007 123 129 (Pubitemid 46020870)
46. Z. Liao, R. Komaki, and L. Milas A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status, inoperable/unresectable non-small cell lung cancer Clin Cancer Res 11 9 2005 3342 3348 (Pubitemid 40627885)
47. L.J. Wirth, R.I. Haddad, and N.I. Linderman Phase I study of gefitinib plus celecoxib in recurrent of metastatic squamous cell carcinoma of head and neck J Clin Oncol 23 28 2005 6976 6981
48. S.F. Dent, and E.A. Eisenhauer Phase I trial design: are new methodologies being put into practice? Ann Oncol 7 1996 561 566 (Pubitemid 26285634)
49. National Cancer Institute, Cancer Therapy Evaluation Program 2003. Available from: http://ctep.cancer.gov/guidelines/templates.html [accessed 14.01.10].
50. Radiation Therapy Oncology Group, Cooperative Group Common Toxicity Criteria. Available from: http://www.rtog.org/members/toxicity/tox.html [accessed 14.01.10.
51. H. Xi, S.E. Baldus, and U. Warnecke-Eberz High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer Clin Cancer Res 11 23 2005 8341 8347 (Pubitemid 41746946)
52. Carbone D, Choy H, Dang T, et al. Serum/plasma VEGF level changes with cyclooxygenase-2 (COX-2) inhibition in combined modality therapy in stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II trial [Abstract]. ASCO Annual Meeting 2002.
53. Y.M. Zhu, N.S.M. Azahri, and D.C. Yu Effects of COX-2 inhibition on expression of vascular endothelial growth factor rand interleukin-8 in lung cancer cells BioMed Central Cancer 8 2008 218